Invention Grant
US09353422B2 USP37 inactivation as a treatment for PLZF/RARA-associated acute promyelocytic leukemia
有权
USP37灭活作为PLZF / RARA相关急性早幼粒细胞白血病的治疗
- Patent Title: USP37 inactivation as a treatment for PLZF/RARA-associated acute promyelocytic leukemia
- Patent Title (中): USP37灭活作为PLZF / RARA相关急性早幼粒细胞白血病的治疗
-
Application No.: US14405085Application Date: 2013-05-31
-
Publication No.: US09353422B2Publication Date: 2016-05-31
- Inventor: Hsiu-Ming Shih , Wei-Chih Yang
- Applicant: Hsiu-Ming Shih , Wei-Chih Yang
- Applicant Address: TW Taipei
- Assignee: ACADEMIA SINICA
- Current Assignee: ACADEMIA SINICA
- Current Assignee Address: TW Taipei
- Agency: Intellectual Property Connections, Inc.
- Agent Hsiu-Ming Saunders
- International Application: PCT/US2013/043750 WO 20130531
- International Announcement: WO2013/184524 WO 20131212
- Main IPC: C07H21/02
- IPC: C07H21/02 ; C07H21/04 ; C12Q1/68 ; C12N15/113 ; G01N33/50
Abstract:
Method of regulating the stability and/or the level of the fusion protein PLZF/RARA are disclosed. Also disclosed are methods for identifying an agent as a regulator of the stability and/or the level of the fusion protein PLZF/RARA. Methods for identifying a therapeutic agent for treating PLZF/RARA-associated acute promyelocytic leukemia (APL) is also disclosed.
Public/Granted literature
- US20150148403A1 USP37 INACTIVATION AS A TREATMENT FOR PLZF/RARA-ASSOCIATED ACUTE PROMYELOCYTIC LEUKEMIA Public/Granted day:2015-05-28
Information query
